India Pharma Outlook Team | Friday, 23 October 2026
The World Health Organization has said the first documented human Shamonda case is unlikely to lead to wider spread.
This is after French authorities reported the infection in a severely immunocompromised patient who later died.
The case was identified in the Lyon area of France in early October.
Officials emphasize it is an isolated incident with no public health risk identified for the general population.
Investigators believe the patient was bitten by an infected midge in eastern France, where the virus had been circulating among livestock earlier in the year.
The patient was a man in his 60s living in the Lyon area. He was already receiving treatment for a serious underlying illness that left him immunocompromised. He died in early October after developing neurological complications that investigators believe were very likely linked to the virus.
French health and agriculture ministries confirmed this as the first documented human detection of Shamonda. The leading hypothesis is that he was bitten by an infected midge in eastern France, where the virus had been circulating among livestock during the spring and summer.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
Shamonda is an orthobunyavirus that primarily affects cattle, sheep, goats, horses, and alpacas. It is spread by biting midges of the Culicoides genus.
Key facts about the virus:
Until this case, the virus was considered non-transmissible to humans.
The WHO told Reuters: “Based on current information and knowledge of the transmission of closely related viruses, this is an isolated human case and it is unlikely to lead to wider spread at this time.”
French authorities stated that no health risk to the general population has been identified. Both the European Centre for Disease Prevention and Control (ECDC) and the WHO are monitoring the situation.
Investigations continue into the exact source of infection, whether the virus contributed to the patient’s death, and the precise transmission route. Given decades of animal circulation without prior human cases, transmission to people appears extremely unusual and limited to this highly vulnerable individual.
Shamonda has expanded across Western Europe in livestock this year, but the human infection remains a single, exceptional case. Authorities stress that clinical, laboratory, and epidemiological investigations are ongoing in coordination with the WHO and ECDC. The message from health officials is clear: while the first human detection is noteworthy, current evidence points to an isolated event with no indication of broader risk.